

Note: Result is presented for the active ingredient, often including more than one brand name

COVID-19 vaccine is an active ingredient

There are **5 099 520** reports with this active ingredient



Reported potential side effects

- › Blood and lymphatic system disorders (2%, 219 805 ADRs)
- › Cardiac disorders (3%, 308 738 ADRs)
- › Congenital, familial and genetic disorders (0%, 3 743 ADRs)
- › Ear and labyrinth disorders (1%, 144 764 ADRs)
- › Endocrine disorders (0%, 11 691 ADRs)
- › Eye disorders (1%, 162 501 ADRs)
- › Gastrointestinal disorders (7%, 850 195 ADRs)
- › General disorders and administration site conditions (26%, 3 062 228 ADRs)
- › Hepatobiliary disorders (0%, 11 739 ADRs)
- › Immune system disorders (1%, 71 705 ADRs)
- › Infections and infestations (5%, 618 737 ADRs)
- › Injury, poisoning and procedural complications (3%, 339 026 ADRs)
- › Investigations (7%, 775 301 ADRs)
- › Metabolism and nutrition disorders (1%, 96 156 ADRs)
- › Musculoskeletal and connective tissue disorders (10%, 1 240 135 ADRs)
- › Neoplasms benign, malignant and unspecified (incl cysts and polyps) (0%, 14 051 ADRs)
- › Nervous system disorders (16%, 1 889 197 ADRs)
- › Pregnancy, puerperium and perinatal conditions (0%, 13 360 ADRs)
- › Product issues (0%, 10 404 ADRs)
- › Psychiatric disorders (2%, 238 709 ADRs)
- › Renal and urinary disorders (0%, 43 497 ADRs)
- › Reproductive system and breast disorders (2%, 270 582 ADRs)
- › Respiratory, thoracic and mediastinal disorders (4%, 523 794 ADRs)
- › Skin and subcutaneous tissue disorders (5%, 576 210 ADRs)
- › Social circumstances (0%, 44 515 ADRs)
- › Surgical and medical procedures (1%, 114 255 ADRs)
- › Vascular disorders (2%, 231 442 ADRs)

Geographical distribution


Patient sex distribution

VigiAccess




Age group distribution

[Chart](#) [Table](#)



ADR reports per year

[Chart](#) [Table](#)



Current data set date is 6/25/2023. The dataset is normally updated on Sundays at 17:00 CET (± 1 hour).

VigiAccess



VigiAccess is developed and maintained by the WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre on behalf of WHO